Switching from anti-CD20 therapies to cladribine and vice versa – Analysis of a German relapsing multiple sclerosis cohort

Anti-CD20 antibodies and cladribine are established therapies for active relapsing multiple sclerosis (RMS). Increasing evidence suggests that switching between these therapies may be beneficial in patients with ongoing disease activity under current treatment. In this multicenter retrospective stud...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Franz Felix Konen, Steffen Pfeuffer, Konstantin Fritz Jendretzky, Klaus Gehring, Birte Elias-Hamp, Kurt-Wolfram Sühs, Stephan Halle, Korbinian Brand, Ralf Lichtinghagen, Eline Willemse, Marc Pawlitzki, Jens Kuhle, Sven G. Meuth, Christoph Kleinschnitz, Refik Pul, Thomas Skripuletz
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Elsevier 2026-01-01
Цуврал:	Neurotherapeutics
Нөхцлүүд:	Active multiple sclerosis Anti-CD20-Therapy Cladribine Switch
Онлайн хандалт:	http://www.sciencedirect.com/science/article/pii/S1878747925002909
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!